title: FAAH inhibitors in the limelight, but regrettably.
abstract: This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the available information on the recent dramatic events.
authors.forename: Christophe
authors.initials: C
authors.lastname: Mallet
authors.forename: Claude
authors.initials: C
authors.lastname: Dubray
authors.forename: Christian
authors.initials: C
authors.lastname: Dualé
mesh_terms: D000581:Amidohydrolases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D001926:Brain Death; D001927:Brain Diseases / Q000139:chemically induced* / Q000401:mortality / Q000503:physiopathology; D017321:Clinical Trials, Phase I as Topic; D003128:Coma / Q000139:chemically induced / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D057239:Early Termination of Clinical Trials; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D000099252:Fatty Acid Amide Hydrolases
chemical_list: D000581:Amidohydrolases; D004791:Enzyme Inhibitors; D000099252:Fatty Acid Amide Hydrolases